These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

44 related articles for article (PubMed ID: 14991829)

  • 1. Genetic influences on cognition in progressive supranuclear palsy.
    Gerstenecker A; Roberson ED; Schellenberg GD; Standaert DG; Shprecher DR; Kluger BM; Litvan I
    Mov Disord; 2017 Dec; 32(12):1764-1771. PubMed ID: 29076559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel
    Li H; Li Q; Weng Q; Cui R; Yen TC; Li Y
    Front Neurol; 2024; 15():1372507. PubMed ID: 38708005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of CSF and plasma NfL and pNfH for Alzheimer's disease diagnosis: a memory clinic study.
    Vrillon A; Ashton NJ; Karikari TK; Götze K; Cognat E; Dumurgier J; Lilamand M; Zetterberg H; Blennow K; Paquet C
    J Neurol; 2024 Mar; 271(3):1297-1310. PubMed ID: 37950758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetics of Multiple System Atrophy and Progressive Supranuclear Palsy: A Systemized Review of the Literature.
    Bougea A
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic and Epigenetic Constructs of Progressive Supranuclear Palsy.
    Debnath M; Dey S; Sreenivas N; Pal PK; Yadav R
    Ann Neurosci; 2022 Apr; 29(2-3):177-188. PubMed ID: 36419517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genotype-Phenotype Correlation in Progressive Supranuclear Palsy Syndromes: Clinical and Radiological Similarities and Specificities.
    Ruiz-Barrio I; Horta-Barba A; Illán-Gala I; Kulisevsky J; Pagonabarraga J
    Front Neurol; 2022; 13():861585. PubMed ID: 35557621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetics of Progressive Supranuclear Palsy: A Review.
    Wen Y; Zhou Y; Jiao B; Shen L
    J Parkinsons Dis; 2021; 11(1):93-105. PubMed ID: 33104043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Appoptosin-Mediated Caspase Cleavage of Tau Contributes to Progressive Supranuclear Palsy Pathogenesis.
    Zhao Y; Tseng IC; Heyser CJ; Rockenstein E; Mante M; Adame A; Zheng Q; Huang T; Wang X; Arslan PE; Chakrabarty P; Wu C; Bu G; Mobley WC; Zhang YW; St George-Hyslop P; Masliah E; Fraser P; Xu H
    Neuron; 2015 Sep; 87(5):963-75. PubMed ID: 26335643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular factors modulating the mechanism of tau protein aggregation.
    Fontaine SN; Sabbagh JJ; Baker J; Martinez-Licha CR; Darling A; Dickey CA
    Cell Mol Life Sci; 2015 May; 72(10):1863-79. PubMed ID: 25666877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Invited review: Frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: a chameleon for neuropathology and neuroimaging.
    Ghetti B; Oblak AL; Boeve BF; Johnson KA; Dickerson BC; Goedert M
    Neuropathol Appl Neurobiol; 2015 Feb; 41(1):24-46. PubMed ID: 25556536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha-synuclein and tau: teammates in neurodegeneration?
    Moussaud S; Jones DR; Moussaud-Lamodière EL; Delenclos M; Ross OA; McLean PJ
    Mol Neurodegener; 2014 Oct; 9():43. PubMed ID: 25352339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of common variability and expression quantitative trait loci for genome-wide associations for progressive supranuclear palsy.
    Ferrari R; Ryten M; Simone R; Trabzuni D; Nicolaou N; Hondhamuni G; Ramasamy A; Vandrovcova J; ; Weale ME; Lees AJ; Momeni P; Hardy J; de Silva R
    Neurobiol Aging; 2014 Jun; 35(6):1514.e1-12. PubMed ID: 24503276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The unfolded protein response is activated in disease-affected brain regions in progressive supranuclear palsy and Alzheimer's disease.
    Stutzbach LD; Xie SX; Naj AC; Albin R; Gilman S; ; Lee VM; Trojanowski JQ; Devlin B; Schellenberg GD
    Acta Neuropathol Commun; 2013 Jul; 1():31. PubMed ID: 24252572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitochondrial dysfunction as a therapeutic target in progressive supranuclear palsy.
    Ries V; Oertel WH; Höglinger GU
    J Mol Neurosci; 2011 Nov; 45(3):684-9. PubMed ID: 21792607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel L284R MAPT mutation in a family with an autosomal dominant progressive supranuclear palsy syndrome.
    Rohrer JD; Paviour D; Vandrovcova J; Hodges J; de Silva R; Rossor MN
    Neurodegener Dis; 2011; 8(3):149-52. PubMed ID: 20838030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progressive supranuclear palsy: pathology and genetics.
    Dickson DW; Rademakers R; Hutton ML
    Brain Pathol; 2007 Jan; 17(1):74-82. PubMed ID: 17493041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a novel risk locus for progressive supranuclear palsy by a pooled genomewide scan of 500,288 single-nucleotide polymorphisms.
    Melquist S; Craig DW; Huentelman MJ; Crook R; Pearson JV; Baker M; Zismann VL; Gass J; Adamson J; Szelinger S; Corneveaux J; Cannon A; Coon KD; Lincoln S; Adler C; Tuite P; Calne DB; Bigio EH; Uitti RJ; Wszolek ZK; Golbe LI; Caselli RJ; Graff-Radford N; Litvan I; Farrer MJ; Dickson DW; Hutton M; Stephan DA
    Am J Hum Genet; 2007 Apr; 80(4):769-78. PubMed ID: 17357082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progressive supranuclear palsy and Parkinson's disease in a family with a new mutation in the tau gene.
    Rossi G; Gasparoli E; Pasquali C; Di Fede G; Testa D; Albanese A; Bracco F; Tagliavini F
    Ann Neurol; 2004 Mar; 55(3):448. PubMed ID: 14991829
    [No Abstract]   [Full Text] [Related]  

  • 19. Tau gene delN296 mutation, Parkinson's disease, and atypical supranuclear palsy.
    Oliva R; Pastor P
    Ann Neurol; 2004 Mar; 55(3):448-9. PubMed ID: 14991828
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.